2-氟乙烷硫代酰胺 | 84350-43-6

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫代酰胺
• 中文名称: 2-氟乙烷硫代酰胺
• 英文名称: 2-fluorothioacetamide
• 英文别名: 2-fluoroethanethioamide
• CAS: 84350-43-6
• 化学式: C₂H₄FNS
• mdl: MFCD19204804
• 分子量: 93.1249
• InChiKey: OHBURFVUAFMQBE-UHFFFAOYSA-N

物化性质

• 沸点：
  159.7±40.0 °C(Predicted)
• 密度：
  1.230±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  5
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  58.1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 储存条件：
  存储条件：2-8°C，避光，惰性气体环境中保存。

反应信息

• 作为反应物：
  描述：

  1-氯-4-三甲基锡-3-丁炔-2-酮 、 2-氟乙烷硫代酰胺 以 N,N-二甲基甲酰胺 为溶剂， 反应 36.0h， 以65%的产率得到2-(fluoromethyl)-4-(2-(trimethylsilyl)ethynyl)thiazole
  参考文献：
  名称：

  Synthesis and Simple ¹⁸F-Labeling of 3-Fluoro-5-(2-(2-(fluoromethyl)thiazol-4-yl)ethynyl)benzonitrile as a High Affinity Radioligand for Imaging Monkey Brain Metabotropic Glutamate Subtype-5 Receptors with Positron Emission Tomography

  摘要：

  2-Fluoromethyl analogs of (3-[(2-methyl-1,3-thiazol-4yl)ethynyl]pyridine) were synthesized as potential ligands for metabotropic glutamate subtype-5 receptors (mGluR5s). One of these, namely, 3-fluoro-5-(2-(2-(fluoromethyl)thiazol-4-yl)ethynyl)benzonitrile (3), was found to have exceptionally high affinity (IC50 = 36 pM) and potency in a phosphoinositol hydrolysis assay (IC50 = 0.714 pM) for mGluR5. Compound 3 was labeled with fluorine-18 (t(1/2) = 109.7 min) in high radiochemical yield (87%) by treatment of its synthesized bromomethyl analog (17) with [F-18]fluoride ion and its radioligand behavior was assessed with positron emission tomography (PET). Following intravenous injection of [F-18]3 into rhesus monkey, radioactivity was avidly taken up into brain with high uptake in mGluR5 receptor-rich regions such as striata. [F-18]3 was stable in monkey plasma and human whole blood in vitro and in monkey and human brain homogenates. In monkey in vivo, a single polar radiometabolite of [F-18]3 appeared rapidly in plasma. [F-18]3 merits further evaluation as a PET radioligand for mGluR5 in human subjects.

  DOI：

  10.1021/jm0701268
• 作为产物：
  描述：

  氟乙酰胺 在 劳森试剂 作用下， 以 六甲基磷酰三胺 为溶剂， 反应 4.0h， 以78%的产率得到2-氟乙烷硫代酰胺
  参考文献：
  名称：

  Synthesis and Simple ¹⁸F-Labeling of 3-Fluoro-5-(2-(2-(fluoromethyl)thiazol-4-yl)ethynyl)benzonitrile as a High Affinity Radioligand for Imaging Monkey Brain Metabotropic Glutamate Subtype-5 Receptors with Positron Emission Tomography

  摘要：

  2-Fluoromethyl analogs of (3-[(2-methyl-1,3-thiazol-4yl)ethynyl]pyridine) were synthesized as potential ligands for metabotropic glutamate subtype-5 receptors (mGluR5s). One of these, namely, 3-fluoro-5-(2-(2-(fluoromethyl)thiazol-4-yl)ethynyl)benzonitrile (3), was found to have exceptionally high affinity (IC50 = 36 pM) and potency in a phosphoinositol hydrolysis assay (IC50 = 0.714 pM) for mGluR5. Compound 3 was labeled with fluorine-18 (t(1/2) = 109.7 min) in high radiochemical yield (87%) by treatment of its synthesized bromomethyl analog (17) with [F-18]fluoride ion and its radioligand behavior was assessed with positron emission tomography (PET). Following intravenous injection of [F-18]3 into rhesus monkey, radioactivity was avidly taken up into brain with high uptake in mGluR5 receptor-rich regions such as striata. [F-18]3 was stable in monkey plasma and human whole blood in vitro and in monkey and human brain homogenates. In monkey in vivo, a single polar radiometabolite of [F-18]3 appeared rapidly in plasma. [F-18]3 merits further evaluation as a PET radioligand for mGluR5 in human subjects.

  DOI：

  10.1021/jm0701268

文献信息

• [EN] THIAZOLE AND OXAZOLE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE À BASE DE THIAZOLE ET D'OXAZOLE
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2009032667A1

  公开（公告）日：2009-03-12

  The present invention provides thiazole and oxazole compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.

  本发明提供噻唑和氧唑化合物，含有这些化合物的组合物，以及用作药用剂的制备方法和使用方法。
• <i>N</i>-Phenylamidines as Selective Inhibitors of Human Neuronal Nitric Oxide Synthase:  Structure−Activity Studies and Demonstration of in Vivo Activity
  作者：Jon L. Collins、Barry G. Shearer、Jeffrey A. Oplinger、Shuliang Lee、Edward P. Garvey、Mark Salter、Claire Duffy、Thimysta C. Burnette、Eric S. Furfine

  DOI：10.1021/jm980072p

  日期：1998.7.1

  the amidine nitrogen and phenyl ring to give N-(3-(aminomethyl)phenyl)acetamidine (14) dramatically altered the selectivity to give a neuronal selective nitric oxide synthase (nNOS) inhibitor. Part of this large shift in selectivity was due to 14 being a rapidly reversible inhibitor of iNOS in contrast to the essentially irreversible inhibition of iNOS observed with 13. Structure-activity studies revealed

  与内皮和诱导型亚型相比，可能需要选择性抑制一氧化氮合酶（NOS）的神经元亚型，以治疗由一氧化氮过量产生引起的神经系统疾病。最近，我们将N-（3-（氨基甲基）苄基）乙am（13）描述为一种缓慢，紧密结合的抑制剂，对人诱导型一氧化氮合酶（iNOS）具有高度选择性。除去the氮和苯环之间的单个亚甲基桥以得到N-（3-（氨基甲基）苯基）乙am（14）极大地改变了选择性，从而得到了神经元选择性一氧化氮合酶（nNOS）抑制剂。选择性大幅度变化的部分原因是14是iNOS的快速可逆抑制剂，而13观察到的iNOS基本上不可逆的抑制。结构活性研究表明，与芳香环相连的碱性胺官能团和空间紧凑的idine是此类NOS抑制剂的关键药效​​团。用N-（3-（氨基甲基）苯基）-2-呋喃基idine啶（77）可获得最大的nNOS抑制能力（Ki-nNOS = 0.006 microM; Ki-eNOS = 0.35 microM;
• Enzyme inhibitors
  申请人：Glaxo Wellsome Inc.

  公开号：US05889056A1

  公开（公告）日：1999-03-30

  A compound of formula (I) ##STR1## wherein R.sup.1 is a C.sub.1-6 straight or branched chain alkyl group, a C.sub.2-6 alkenyl group, a C.sub.2-6 alkynyl group, a C.sub.3-6 cycloalkyl group or a C.sub.3-6 cycloalkylC.sub.1-6 alkyl group, each optionally substituted by one to three groups independently selected from: --CN; --NO.sub.2 ; a group --COR.sup.2 wherein R.sup.2 is hydrogen, C.sub.1-6 alkyl, --OR.sup.3 wherein R.sup.3 is hydrogen or C.sub.1-6 alkyl or NR.sup.4 R.sup.5 wherein R.sup.4 and R.sup.5 are independently selected from hydrogen or C.sub.1-6 alkyl; a group --S(O).sub.m R.sup.6 wherein m is 0, 1 or 2, R.sup.6 is hydrogen, C.sub.1-6 alkyl, hydroxy or NR.sup.7 R.sup.8 wherein R.sup.7 and R.sup.8 are independently hydrogen or C.sub.1-6 alkyl; a group PO(OR.sup.9).sub.2 wherein R.sup.9 is hydrogen or C.sub.1-6 alkyl; a group NR.sup.10 R.sup.11 wherein R.sup.10 and R.sup.11 are independently selected from hydrogen, C.sub.1-6 alkyl, --COR.sup.12 wherein R.sup.12 is hydrogen or C.sub.1-6 alkyl, or --S(O).sub.m' R.sup.13 wherein m' is 0, 1 or 2 and R.sup.13 is hydrogen or C.sub.1-6 alkyl; halo; or a group --OR.sup.14 wherein R.sup.14 is hydrogen, C.sub.1-6 alkyl optionally substituted by one to three halo atoms, C.sub.6-10 aryl or --COR.sup.15 wherein R.sup.15 is hydrogen or C.sub.1-6 alkyl; p is 2 or 3, q is 1 or 2 and n is 0 or 1 and all salts, esters, amides and physiologically acceptable prodrugs thereof; pharmaceutical uses and formulations therefor; and processes for their preparation are disclosed.

  化合物的化学式为（I）##STR1## 其中R.sup.1是C.sub.1-6直链或支链烷基，C.sub.2-6烯基，C.sub.2-6炔基，C.sub.3-6环烷基或C.sub.3-6环烷基C.sub.1-6烷基，每个基可选地被一个到三个基所取代，这些基是独立选择的：--CN; --NO.sub.2; 一个基--COR.sup.2，其中R.sup.2是氢，C.sub.1-6烷基，--OR.sup.3，其中R.sup.3是氢或C.sub.1-6烷基或NR.sup.4R.sup.5，其中R.sup.4和R.sup.5分别是氢或C.sub.1-6烷基; 一个基--S(O).sub.mR.sup.6，其中m为0、1或2，R.sup.6为氢，C.sub.1-6烷基，羟基或NR.sup.7R.sup.8，其中R.sup.7和R.sup.8独立地为氢或C.sub.1-6烷基; 一个基PO(OR.sup.9).sub.2，其中R.sup.9是氢或C.sub.1-6烷基; 一个基NR.sup.10R.sup.11，其中R.sup.10和R.sup.11独立地选择自氢、C.sub.1-6烷基、--COR.sup.12，其中R.sup.12是氢或C.sub.1-6烷基，或--S(O).sub.m' R.sup.13，其中m'为0、1或2，R.sup.13为氢或C.sub.1-6烷基; 卤素; 或一个基--OR.sup.14，其中R.sup.14是氢，C.sub.1-6烷基，可选地被一个到三个卤素原子取代的C.sub.1-6烷基，C.sub.6-10芳基或--COR.sup.15，其中R.sup.15是氢或C.sub.1-6烷基; p为2或3，q为1或2，n为0或1，以及所有的盐，酯，酰胺和生理上可接受的前药；公开了其药物用途和制剂；以及其制备过程。
• Thiazole And Oxazole Kinase Inhibitors
  申请人：Adjabeng George

  公开号：US20110098296A1

  公开（公告）日：2011-04-28

  The present invention provides thiazole and oxazole compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.

  本发明提供了噻唑和异噁唑化合物，包含它们的组合物，以及制备它们的方法和用作药物的方法。
• USRE039576E1
  申请人：——

  公开号：——

  公开（公告）日：——